Press release, Helsinki, 13 December 2024 at 9 AM (EET)
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that it has received an order for an NBS 5+ system from a private clinic customer in the United States. The customer is an experienced Nexstim system user that is now purchasing a system for a new clinic location.
The NBS (Navigated Bran Stimulation) 5+ is a system configuration that enables the delivery of both diagnostic and therapeutic applications in the same device. The customer will primarily use the system to treat Major Depressive Disorder (MDD), for which the system is FDA cleared. The diagnostic indication of the system is non-invasive, pre-surgical mapping of motor cortices prior to neurosurgery.
Mikko Karvinen, CEO of Nexstim, comments: “Our customer base consists of a large variety of healthcare providers. What they have in common is that they appreciate the high-quality technology that Nexstim offers. We are happy to work with skilled professionals like this customer that are committed to offering the best, personalized care for their patients.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com